Life Tech收购促使赛默飞世尔Q2增长33%

  • Life Tech,赛默飞Q2,赛默飞世尔,收购,Life Sciences Solutions
  • 生物通

赛默飞世尔科技今天宣布,其第二季度的收入同比增长33%,这主要是由生命科学解决方案(Life Sciences Solutions)部门的大幅增长所带动的。

在截至6月28日的三个月内,该公司的总收入达43.2亿美元,与去年第二季度的32.4亿美元相比增长33%,也超出华尔街普遍预计的42.5亿美元。据赛默飞世尔介绍,有机增长达5%,而货币换算增加了1个百分点。收购和净资产剥离,增加了27个百分点。

按部门来看,生命科学解决方案的收入从去年同期的1.81亿美元增长到11.0亿美元,这主要归因于今年2月完成的对Life Technologies的收购。在财报发布后的电话会议上,赛默飞世尔的CFO Pete Wilver表示,这一部门的生物制品业务,以及细胞生产和新一代测序仍保持强劲的增长势头,这部分被较低的特许权使用费所抵消。

对于赛默飞世尔的其他部门,分析仪器收入从7.61亿美元增长到7.934亿美元,专业诊断从7.936亿美元增长8.551亿美元,而实验室产品和服务从16.0亿美元增长到17.0亿美元。

Wilver表示,质谱业务,作为分析仪器的一部分,在第二季度有着“非常强劲的增长”,而这项业务,以及新一代测序,被CEO Marc Casper认为是未来6-12个月公司的增长动力。

按终端市场来看,Casper称制药/生物技术是赛默飞世尔的“一个了不起的故事”,在Q2有着高的个位数增长。科研/政府市场则在低的个位数,因为美国的资助刚开始发放。工业/应用市场也在低的个位数,而诊断/医疗保健则在个位数中值。

赛默飞世尔的北美和欧洲业务在第二季度有增长,但中国却和去年同期持平,这与政府资助发放较慢有关。Casper表示,他们仍然对中国的增长前景充满信心。

在这一季度,赛默飞世尔的利润为2.785亿美元,摊薄每股收益0.69美元。不按美国通用会计准则(non-GAAP)计算,每股收益为1.72美元,超过分析师普遍预计的1.62美元。

赛默飞世尔Q2的研发费用同比增长90%,从去年的9670万美元增长到1.837亿美元,而销售、管理及行政费用增长40%,从7.344亿美元增长到10.2亿美元。重组及其他费用也从一年前的2150万美元增长到6090万美元,而与收购相关的无形资产摊销也从1.912亿美元增长到3.436亿美元。

在本季度末,赛默飞世尔拥有5.849亿美元的现金及现金等价物,以及2100万美元的短期投资。

This link:http://www.chemcd.com/news/1168.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Prime Therapeutics urges FDA to keep current, consistent naming conventions for biologics, biosimilars

Prime Therapeutics, LLC (Prime) has submitted comments to the U.S. Food and Drug Administration (FDA) in support of two citizen petitions on the naming of biosimilar drugs. Biosimilars are medically equivalent versions of biologics, used to treat complex illnesses such as cancer.

FDA Approves Pembrolizumab for Advanced Melanoma

Today the FDA approved Keytruda (pembrolizumab), a new treatment for advanced melanoma, the deadliest form of skin cancer. Melanoma patients have been waiting anxiously for this day, given the promising data that early studies have shown.

Epoxy Resin Market Worth $9.2 Billion by 2019

"Epoxy Resin market by Application (Coatings, Electronics, Construction, Wind Turbine, Composites, and Adhesives) and Geography - Trends & Forecast to 2019" by MarketsandMarkets, the market of epoxy resin is projected to grow from an estimated $5,995.8 million in 2013 to $9,219.1 million by 2019, with a CAGR of 7.4% between 2014 and 2019.

GSK receives FDA approval of an additional Promacta (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)

FDA has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta(eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).

FDA Approves The Medicines Company's ORBACTIV™ (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections

FDA Approves The Medicines Company's ORBACTIV? (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections First and Only Single Dose Antibiotic for the Treatment of Skin Infections Caused by Susceptible Designated Gram-positive Bacteria ORBACTIV?U.S. Launch Expected in 2H/2014

AstraZeneca and QIAGEN enter collaboration to develop diagnostic test for lung cancer patients suitable for treatment with IRESSA

AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA?.

Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading.